Business Context and Reporting Period
Company: Personalis, Inc. (PSNL)
Filing Type: Form 8-K (Current Report)
Date of Report: July 20, 2026
Event: Entry into a Material Definitive Agreement (Agreement and Plan of Merger) with Tempus AI, Inc. ("Tempus" or "Parent").
Personalis, Inc. has entered into a merger agreement to be acquired by Tempus AI, Inc. The transaction involves a two-step merger where Personalis will become a wholly-owned subsidiary of Tempus. The Company's Board of Directors has approved the agreement and recommends it to stockholders.
Key Financial Metrics and Transaction Terms
Consideration to Stockholders:
- Base Consideration: $16.25 per share in cash or Tempus Class A Common Stock.
- Exchange Ratio:
- If Tempus Stock Price is $\le$ $48.42 (Floor Price): Fixed ratio of 0.3356 shares of Tempus stock per Personalis share.
- If Tempus Stock Price is > $48.42: Ratio equals $16.25 divided by the Tempus Stock Price.
- Cash Election: Tempus may elect to pay cash for up to 50% of the aggregate outstanding shares at $16.25 per share.
Termination Fees:
- Company Fee: Approximately $76.8 million payable to Tempus if Personalis terminates due to a Superior Proposal or changes its recommendation.
- Reverse Termination Fee: Approximately $76.8 million payable by Tempus to Personalis if the deal fails due to regulatory restraints (primarily due to Tempus breach) or if the deal does not close by the Outside Date (April 20, 2027, subject to extensions).
Equity Award Treatment:
- In-the-Money Options: Converted to Stock Consideration or assumed by Tempus with adjusted exercise prices.
- Out-of-the-Money Options: Cancelled without consideration.
- RSUs: Accelerated for non-employee directors; assumed and converted for others.
- PSUs: Partial acceleration based on elapsed time; remainder assumed and converted.
Note: This filing does not provide Personalis's standalone revenue, profit, cash flow, or debt metrics for the reporting period.
Material Changes and Conditions
Material Change: The Company is no longer an independent public entity pending the consummation of the merger. The transaction is subject to customary closing conditions, including:
- Approval by a majority of Personalis stockholders.
- Effectiveness of a Form S-4 registration statement.
- Regulatory approvals (including HSR Act waiting period expiration).
- Absence of a Material Adverse Effect on either party.
- Receipt of a tax opinion confirming reorganization status.
Voting Agreement: Merck Sharp & Dohme LLC, holding approximately 13% of Personalis's voting power, has entered into a Voting Agreement to support the merger and vote against competing proposals.
Guidance, Outlook, and Risks
Outlook: The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code. The "Outside Date" for closing is April 20, 2027, with provisions for two six-month extensions.
Risks and Contingencies:
- Stockholder Approval: The deal requires affirmative vote by Personalis stockholders.
- Regulatory Risk: Failure to obtain antitrust or other regulatory approvals could trigger the reverse termination fee or deal termination.
- Market Risk: The stock consideration value fluctuates based on Tempus's stock price, subject to a floor price mechanism.
- Operational Disruption: Risks related to integrating operations, employee retention, and diversion of management attention.
- Superior Proposal: Personalis retains a fiduciary out to consider superior proposals, subject to a termination fee.
Investor Verification Checklist
- Form S-4 and Proxy Statement: Review the upcoming registration statement for detailed financial data, risk factors, and the full text of the Merger Agreement.
- Stockholder Vote: Confirm the date and procedures for the special meeting of stockholders to approve the merger.
- Tempus Stock Price: Monitor Tempus's stock price to calculate the potential Exchange Ratio if it exceeds the $48.42 floor.
- Regulatory Status: Track the status of HSR Act filings and other regulatory clearances.
- Equity Award Impact: Verify specific treatment of individual equity awards (options, RSUs, PSUs) based on vesting status and type.
- Merck Support: Note that Merck's 13% stake is committed to voting in favor, reducing the threshold for approval.